NY-ESTÉE-LAUDER
26.6.2020 14:02:11 CEST | Business Wire | Press release
This week, The Estée Lauder Companies (NYSE:EL) announced that Stéphane de La Faverie has been promoted to Group President, while continuing in his role as Global Brand President, Estée Lauder and AERIN. He will report directly to Fabrizio Freda, President and Chief Executive Officer in his role as Group President, and will continue to report to Jane Hertzmark Hudis, Executive Group President, for his Global Brand President responsibilities for Estée Lauder and AERIN. As Group President, Stéphane’s new portfolio of brands will include Jo Malone London, Aramis and Designer Fragrances, Le Labo, Darphin, Lab Series, By Kilian, Editions de Parfums Frédéric Malle, RODIN olio lusso and Prescriptives.
“Stéphane has extensive expertise leading brands, making him well suited to the significant leadership responsibilities of the Group President role,” said Fabrizio Freda. “As Global Brand President, Estée Lauder and AERIN, he has been the ideal leader to bring our company’s iconic namesake brand into an incredible phase of broad-based growth. His well-deserved promotion reflects his excellent track record of building and leading global brands, his expertise across categories and channels, and a keen understanding of local relevance.”
As Group President, Stéphane will oversee and drive ELC’s recently-announced third brand cluster, which is focused primarily on artisanal and luxury fragrances. In addition to the Company’s enterprise fragrance strategy, Stéphane will leverage his skin care expertise to drive differentiation for cult-favorite brands in this category, as well as opportunities in China and Travel Retail.
Stéphane was named Global Brand President of Estée Lauder and AERIN in July 2016, and his successful leadership has driven Estée Lauder’s tremendous global performance across demographics, regions and channels. Under his oversight, Estée Lauder continues to exercise its power of recruitment and loyalty around the world, with a special focus on Chinese consumers globally. The brand’s hero strategy continues to demonstrate its strength across existing, globally iconic franchises like Advanced Night Repair and Double Wear.
Stéphane’s unique ability to cultivate and honor the brand’s authentic roots while simultaneously connecting with consumers of all ages, backgrounds and ethnicities, has helped make Estée Lauder one of the world’s most beloved prestige beauty brands. He has continued to reinforce Estée Lauder’s aspirational positioning through elevated brand storytelling and disruptive partnerships including cult streetwear designer KITH and Japanese graffiti artist LADY AIKO.
Stéphane is a proactive leader who is passionate about talent development, always leading by example and constantly learning from his teams, both in New York and around the world. Prior to his time at Estée Lauder, Stéphane was Global Brand President, Origins and Darphin, where he led Origins’ rapid double-digit growth in China, while simultaneously reinvigorating the brand’s footprint in heritage markets such as North America through innovative retail capabilities. Notably, he has also played an important leadership role in the Company’s fragrance portfolio, having served as Senior Vice President/Global General Manager, Aramis and Designer Fragrances.
About The Estée Lauder Companies Inc.|
The Estée Lauder Companies Inc.
is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Prescriptives, Lab Series, Origins, Tommy Hilfiger, M·A·C, Kiton, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin, Tom Ford, Smashbox, Ermenegildo Zegna, AERIN, RODIN olio lusso, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, By Kilian, BECCA, Too Faced and Dr. Jart+.
ELC-L
ELC-C
ELC-B
View source version on businesswire.com: https://www.businesswire.com/news/home/20200626005188/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Owkin to License K Pro AI Scientist and Multimodal Oncology and Immunology Datato Boehringer Ingelheim2.9.2026 14:00:00 CEST | Press release
Owkin, the agentic AI company striving to transform drug discovery and development for biopharma, today announced a license agreement with Boehringer Ingelheim for K Pro, Owkin’s AI Scientist, together with multimodal patient data, aiming to speed up the discovery process across multiple indications in oncology and immunology. This agreement builds upon an initial pilot undertaken by Owkin with Boehringer in 2025. In that pilot Owkin delivered deep spatial insights into the tumor microenvironment of a gene target through its MOSAIC dataset. Under the new agreement, Owkin will license multimodal oncology data to Boehringer and will generate new multimodal data in immunology. Owkin licenses, sources and generates multimodal patient data in collaboration with its global patient data network. Boehringer Ingelheim’s teams will access and analyze this data through K Pro, which provides a single environment to interrogate data and run reproducible analyses. K Pro’s reasoning capabilities supp
Biocytogen Enters into Non-Exclusive Licensing Agreement with Qilu Pharmaceutical for a Fully Human VHH Antibody to Support Innovative Drug Development in Neuroscience2.9.2026 14:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, SSE: 688796; HKEX: 02315) today announced that it has entered into a non-exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd. (“Qilu Pharmaceutical”) for a fully human VHH antibody molecule. Under the agreement, Biocytogen will grant Qilu Pharmaceutical non-exclusive rights to a fully human VHH antibody molecule to support its research and development of innovative therapeutics in the neuroscience field. The licensed VHH antibody molecule was generated from Biocytogen’s proprietary RenNano® platform. The RenNano® platform is designed to discover fully human VHH antibody molecules with favorable specificity, binding affinity, and developability, and can generate molecular building blocks for the design and development of VHH antibodies, bispecific/multispecific antibodies, antibody-drug conjugates, and other innovative modalities. Through this license, Qilu Pharmaceutical may advance the research and development o
Croma-Pharma Introduces Electronic Instructions for Use Across the saypha® Portfolio2.9.2026 13:37:00 CEST | Press release
Healthcare professionals in eligible markets can now access the Instructions for Use for the saypha® portfolio digitally by scanning a QR code on the product packaging Croma-Pharma has introduced electronic Instructions for Use (eIFU) across its saypha® portfolio in markets where applicable regulations permit electronic Instructions for Use to replace printed versions. The transition expands digital access to essential product information for healthcare professionals while reducing the use of printed documentation. Healthcare professionals can access the current approved Instructions for Use by scanning the QR code on the saypha® folding box. The eIFU platform provides direct digital access to the latest approved Instructions for Use. "Innovation extends beyond product development. It also includes how we provide healthcare professionals with access to essential product information," said Andreas Prinz, Chief Executive Officer of Croma-Pharma. "The introduction of electronic Instructio
Moving Forward in Oman: Orascom, Samih Sawiris and Muriya Keep Building2.9.2026 13:13:00 CEST | Press release
Orascom and Muriya press ahead across Hawana Salalah, Jebel Sifah and the US$90M+ As Sodah Island, signalling long-term conviction in Oman’s future, in step with Vision 2040. Across Oman, Orascom Development and its Sultanate platform, Muriya, are moving forward. While parts of the region grow cautious, Muriya has paused nothing, building and delivering across all three destinations: Hawana Salalah, Jebel Sifah and As Sodah Island. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260902781576/en/ Moving Forward in Oman: Orascom, Samih Sawiris and Muriya Keep Building (Photo: AETOSWire) The same steadiness runs through everything Samih Sawiris and Orascom have built, from El Gouna to Andermatt to Mamula Island: identifying extraordinary places and developing them for the long term. “Oman has everything we look for as a long-term developer: stability, natural beauty, and a clear direction for its future. Our continued investment
Aukera Closes €460 Million Structured Credit Facility Led by EIG to Support European Energy Infrastructure Portfolio2.9.2026 13:00:00 CEST | Press release
Aukera, the pan-European battery storage and renewable energy platform backed by AtlasInvest, Reggeborgh and SFPIM (Belgium's sovereign wealth fund), announced the closing of its €460 million structured credit facility, for which EIG, a leading institutional investor in the global energy and infrastructure sectors, served as the lead investor. With the financing in place, Aukera moves into its next phase of growth, combining capital, expertise and delivery capability to build a significant European energy infrastructure platform that develops, finances, constructs and operates assets at scale. The original facility included an initial €200 million commitment and an accordion feature of up to €250 million. The amended facility converts that accordion into a firmly committed €260 million Series 2 tranche, increasing total committed capital to €460 million. The additional capital will support the continued advancement of Aukera's portfolio of renewable energy generation, battery storage a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
